

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Conklin

Serial No.

09/441,318

Filed:

11/16/99

For:

TRANSGENIC PLANT WITH INCREASED EXPRESSION OF

GDP-MANNOSE PYROPHOSPHORYLASE

Examiner:

Kubelik, A.

Art Unit:

1638

Attorney Docket No.: BTI-41

REPLY TO FINAL OFFICE ACTION

HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

In response to the Office Action dated January 8, 2002, please amend the above-identified application as follows.

In the Claims:

Pursuant to 37 C.F.R. § 1.121(c)(1), amendments to claims 1, 16, and 20 are hereby made by the below rewriting of said claims, in clean form, with all changes included. Pursuant to 37 C.F.R. § 1.121(c)(1)(ii), please find attached hereto one or more pages, marked up to show all changes relative to the previous version of each claim so amended.

1. (Twice Amended) A genetically engineered plant, or portion thereof, comprising a recombinant nucleic acid that encodes an enzyme in a plant Vitamin C biosynthesis pathway, wherein said enzyme is selected from the group consisting of phosphoglucose isomerase, phosphomannomutase, GDP-mannose pyrophosphorylase, and GDP-Dmannose-3,5-epimerase.

CERTIFICATE OF FACSIMILE TRANSMISSION FACSIMILE NO: 903-308-4242 DATE: 4/1/02 I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, to the facsimile number and on the date indicated above. Meghan Van Leeuwen